

AUG. 16. 2006 3:03PM MOFO 28TH FL

RECEIVED
CENTRAL FAX CENTER

NO. 384 P. 4

AUG 16 2006

Application No.: 09/623,533

2

Docket No.: 500862001520

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Claim 1 (previously presented): An anti-viral peptide-albumin conjugate comprising: an anti-viral peptide comprising a maleimide containing group and an amino acid sequence, wherein said sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits an anti-viral activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said peptide-albumin conjugate wherein the ratio of peptide to albumin in said conjugate is 1:1 .

Claim 2-3 (canceled).

Claim 4 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 1.

Claim 5 (canceled).

Claim 6 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 7-18 (canceled).

Claim 19 (previously presented): A composition for use in the treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an anti-viral peptide-albumin conjugate comprising an anti-viral peptide comprising a maleimide containing group and an amino acid sequence wherein said sequence is selected from the group consisting of

Application No.: 09/623,533

3

Docket No.: 500862001520

SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541, wherein said sequence exhibits an anti-viral activity against human immunodeficiency virus (HIV) and said peptide is covalently bonded to cysteine 34 of albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to albumin in said conjugate is 1:1.

Claim 20 (canceled).

Claim 21 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 1.

Claims 22-30 (canceled).

Claim 31 (previously presented): The composition of claim 19 wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 32-35 (canceled).

Claim 36 (previously presented): A composition comprising the anti-viral peptide-albumin conjugate of claim 1 in a physiologically acceptable medium.

Claim 37 (canceled).

Claim 38 (previously presented): The composition of claim 36 wherein said amino acid sequence is SEQ ID NO: 1.

Claim 39 (previously presented): The composition of claim 36 wherein said amino acid sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 534, SEQ ID NO: 535, SEQ ID NO:

Application No.: 09/623,533

4

Docket No.: 500862001520

536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540, and SEQ ID NO: 541.

Claims 40-58 (canceled).

Claim 59 (currently amended): The anti-viral peptide-albumin conjugate of claim 1 wherein said albumin is in blood serum albumin.

Claim 60 (currently amended): The anti-viral peptide-albumin conjugate of claim 59 wherein said blood is in a albumin is human serum albumin.

Claim 61 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 3.

Claim 62 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 4.

Claim 63 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 5.

Claim 64 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 117.

Claim 65 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 118.

Claim 66 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 119.

Claim 67 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 534.

Claim 68 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 535.

Application No.: 09/623,533

5

Docket No.: 500862001520

Claim 69 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 536.

Claim 70 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 537.

Claim 71 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 538.

Claim 72 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 539.

Claim 73 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 540.

Claim 74 (previously presented): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO: 541.

Claim 75 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 3.

Claim 76 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 4.

Claim 77 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 5.

Claim 78 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 117.

Claim 79 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 118.

Application No.: 09/623,533

6

Docket No.: 500862001520

Claim 80 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 119.

Claim 81 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 534.

Claim 82 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 535.

Claim 83 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 536.

Claim 84 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 537.

Claim 85 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 538.

Claim 86 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 539.

Claim 87 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 540.

Claim 88 (previously presented): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO: 541.